PURPOSE OF REVIEW: Although enormous progress has been made in treating non-Hodgkin's lymphoma (NHL), and some patients can be cured with combination immunochemotherapy, patients with relapsed and refractory lymphoma often succumb to their disease. Advances in our understanding of lymphoma biology and molecular pathogenesis are yielding new therapeutic targets. RECENT FINDINGS: This article reviews NHL biology and describes how our understanding of molecular pathogenesis is leading to the discovery of many therapeutic targets, including the cell signaling and cell cycle regulatory proteins, pro-apoptotic family members, the B-cell antigen receptor (BCR), and histone deacetylase. Recent preclinical and clinical data with inhibitors of phosphatidylinositol 3-kinase, AKT, mammalian target of rapamycin, histone deacetylase, bcl-2, and the Bruton's tyrosine kinase, a pivotal enzyme in the BCR pathway, are discussed. SUMMARY: Understanding these novel targets in the context of NHL biology will bring new therapies and allow us to develop new therapeutic platforms for the treatment of relapsed and refractory NHL, and will hopefully improve the clinical outcome for these patients.
PURPOSE OF REVIEW: Although enormous progress has been made in treating non-Hodgkin's lymphoma (NHL), and some patients can be cured with combination immunochemotherapy, patients with relapsed and refractory lymphoma often succumb to their disease. Advances in our understanding of lymphoma biology and molecular pathogenesis are yielding new therapeutic targets. RECENT FINDINGS: This article reviews NHL biology and describes how our understanding of molecular pathogenesis is leading to the discovery of many therapeutic targets, including the cell signaling and cell cycle regulatory proteins, pro-apoptotic family members, the B-cell antigen receptor (BCR), and histone deacetylase. Recent preclinical and clinical data with inhibitors of phosphatidylinositol 3-kinase, AKT, mammalian target of rapamycin, histone deacetylase, bcl-2, and the Bruton's tyrosine kinase, a pivotal enzyme in the BCR pathway, are discussed. SUMMARY: Understanding these novel targets in the context of NHL biology will bring new therapies and allow us to develop new therapeutic platforms for the treatment of relapsed and refractory NHL, and will hopefully improve the clinical outcome for these patients.
Authors: Kacey L Sachen; Michael J Strohman; Jonathan Singletary; Ash A Alizadeh; Nicole H Kattah; Chen Lossos; Elizabeth D Mellins; Shoshana Levy; Ronald Levy Journal: Blood Date: 2012-09-28 Impact factor: 22.113
Authors: Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore Journal: Nat Med Date: 2013-01-06 Impact factor: 53.440
Authors: Beata Holkova; Maciej Kmieciak; Prithviraj Bose; Victor Y Yazbeck; Paul M Barr; Mary Beth Tombes; Ellen Shrader; Caryn Weir-Wiggins; April D Rollins; Erin M Cebula; Emily Pierce; Megan Herr; Heidi Sankala; Kevin T Hogan; Wen Wan; Changyong Feng; Derick R Peterson; Richard I Fisher; Steven Grant; Jonathan W Friedberg Journal: Leuk Lymphoma Date: 2015-10-12
Authors: E Decaup; C Jean; C Laurent; P Gravelle; S Fruchon; F Capilla; A Marrot; T Al Saati; F-X Frenois; G Laurent; C Klein; N Varoqueaux; A Savina; J-J Fournié; C Bezombes Journal: Blood Cancer J Date: 2013-08-09 Impact factor: 11.037
Authors: Kandasamy Hariharan; Peter Chu; Tracey Murphy; Dana Clanton; Lisa Berquist; Arturo Molina; Steffan N Ho; Mario I Vega; Benjamin Bonavida Journal: Int J Oncol Date: 2013-06-13 Impact factor: 5.650